Please take 10 minutes to complete this survey to help us put myeloma on New Zealand’s health agenda and help you to have the best lives possible. The survey will be open until 3 September. https://www.surveymonkey.com/r/8YBXM78Continue Reading

A year after the first CAR T-cell therapy was approved to treat pediatric patients with relapsed and/or refractory CD19-positive acute lymphoblastic leukemia (ALL), researchers have issued guidelines to help healthcare professionals recognize and treat the associated adverse events (AEs) from this treatment. While the guidelines are intended for all healthcare professionals—from emergency room and neurology...Continue Reading

A supplemental biologics license application (sBLA) for elotuzumab (Empliciti) has been granted a priority review by the FDA for use in combination with pomalidomide (Pomalyst) and low-dose dexamethasone (EPd) as a treatment for patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor (PI). The application is based on...Continue Reading